Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Virtual Advanced Course on EGFR-Mutated NSCLC 2021

ESMO-Virtual-Advanced-Course-EGFR-Mutated-NSCLC-1000x250-June
Start date
21 Jun 2021
End date
23 Jun 2021
Location
Virtual, GMT +8

The course will start at 3 pm - Singapore local time (GMT+8)​

Learning objectives

  • Understanding the biology of EGFR in normal and malignant cells
  • Gaining insights in the spectrum of EGFR activating mutations, platforms, and strategies for molecular testing
  • Understanding the role of biomarkers in selecting NSCLC patients for EGFR TKIs
  • Discussing state-of-the-art therapeutic strategies and clinical research in EGFR mutated NSCLC
  • Managing toxicity and how to use EGFR TKIs in specific subgroups of patients

Download the programme

This course is part of a of a three-steps ESMO global programme on EGFR. The programme is organised into three parts, an education segment (with two educational courses) and a hospital visit segment hosted by partner institutes:

  • ESMO Virtual Preceptorship on NSCLC held on 6-8 May 2021
  • ESMO Virtual Advanced Course on EGFR-mutated NSCLC to be held on 21-23 June 2021
  • A 4-days hospital based practical experience in selected European host institutes (dates for this will be proposed considering both the status of the pandemic and the availability of the host centres. Most likely, it will not be possible to organize site visits until the end of 2021

Applications for this event are closed. The course is open only to the participants who have been selected and attended the ESMO Virtual Preceptorship on NSCLC held on 6-8 May 2021.

Accreditation

The programme of this virtual event has been accredited with 9 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.

Co-Chairs

  • Pasi A. Jänne, United States
  • Tony S. K. Mok, Hong Kong
  • Solange Peters, Switzerland

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings